Rare diseases
Investigational molecules
Locations
Recruiting trials first
6 clinical trials in this condition
Greece
France
Bulgaria
AustriaIn short
Still's disease is a rare inflammatory condition that causes daily fevers, a distinctive rash, and joint pain, typically affecting young adults between ages 16 and 35. The path to controlling symptoms often involves a combination of medicines—from common pain relievers to cutting-edge biological therapies—and finding the right treatment can be a process of trial and adjustment.
When someone receives a diagnosis of Still's disease, the immediate focus shifts to managing the inflammation that drives this condition. Treatment aims to reduce pain, control fever, prevent joint damage, and improve the overall quality of life. Because Still's disease can follow different patterns in different people—sometimes appearing once and disappearing, sometimes returning in episodes, or sometimes persisting chronically—doctors must tailor treatment to each individual's disease course and symptom severity.
The medical approach to Still's disease recognizes that this is not simply about making symptoms bearable. Without proper treatment, the condition can cause serious complications including permanent joint damage (particularly to the wrists), liver problems, heart inflammation, and lung issues. In rare cases, a life-threatening complication called macrophage activation syndrome (a severe overactivation of immune cells) can occur. This makes timely and effective treatment essential, even during periods when symptoms seem to have calmed down.
Current medical guidelines recognize several approved treatment options that have proven effective for many patients. At the same time, researchers continue to explore new therapies in clinical trials, testing innovative approaches that may offer better outcomes for people who don't respond well to standard treatments or who experience difficult side effects.
The foundation of Still's disease treatment typically begins with medicines designed to reduce inflammation and control pain. The choice of medication depends on how severe the symptoms are, how the disease is behaving, and how well a patient tolerates different drugs.
Nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, are often the first medicines tried for people with milder symptoms. These include medications like ibuprofen (sold as Advil or Motrin) and naproxen sodium (sold as Aleve). Stronger prescription NSAIDs are also available. These drugs work by blocking enzymes in the body that create inflammation. While NSAIDs can be effective for joint pain and mild inflammation, they carry a risk of liver damage, especially with long-term use. Because of this, patients taking NSAIDs regularly need periodic blood tests to monitor their liver function.
When NSAIDs alone aren't sufficient—which is often the case with Still's disease—doctors turn to corticosteroids, with prednisone being the most commonly used. These powerful anti-inflammatory medicines work by suppressing the immune system's overactive response. Many people with Still's disease require corticosteroid treatment to bring their symptoms under control. Prednisone can be remarkably effective at reducing fever, rash, and joint inflammation, often providing relief within days.
For patients who need ongoing treatment or who experience disease recurrence, doctors often add a disease-modifying antirheumatic drug (DMARD) to the treatment plan. Methotrexate (sold as Trexall) is the most commonly used DMARD for Still's disease. It works by interfering with the body's production of inflammatory substances. Methotrexate is frequently combined with prednisone, which allows doctors to reduce the prednisone dose while maintaining disease control. This combination approach can minimize the side effects associated with long-term steroid use.
When standard treatments with NSAIDs, corticosteroids, and methotrexate don't provide adequate relief, or when patients develop severe or chronic forms of the disease, physicians turn to biologic therapies. These are a newer class of medicines called biologic response modifiers, or simply biologics, which target specific proteins in the immune system that drive inflammation.
Three biologic medicines have proven particularly useful for treating Still's disease. Anakinra (sold as Kineret) blocks a protein called interleukin-1 (IL-1), which plays a central role in the inflammation seen in Still's disease. Canakinumab (sold as Ilaris) also targets IL-1 but works in a slightly different way than anakinra. Tocilizumab (sold as Actemra) blocks a different inflammatory protein called interleukin-6 (IL-6). These medicines are given by injection or intravenous infusion and have helped many patients who didn't respond to other treatments.
An important aspect of Still's disease treatment is something called maintenance therapy. Even after symptoms disappear, doctors often recommend continuing medication for some time. This approach helps prevent flare-ups and protects joints and organs from damage. The duration of treatment varies considerably—some people may need medication for months, while others require years of treatment. Regular monitoring through blood tests and medical examinations helps doctors adjust treatment as needed.
While standard treatments help many people with Still's disease, researchers continue to investigate new therapies that might work better, cause fewer side effects, or help patients who don't respond to currently available medicines. Clinical trials are research studies that carefully test new treatments in volunteer patients to see if they are safe and effective.
Much of the clinical research in Still's disease focuses on better understanding which inflammatory molecules drive the disease. Scientists have learned that substances called cytokines—chemical messengers that immune cells use to communicate—are overproduced in Still's disease. Specifically, interleukin-1 (IL-1) and interleukin-18 (IL-18) appear to be key players. This understanding has led researchers to develop and test medicines that specifically block these inflammatory signals.
Clinical trials examining Still's disease treatments typically follow a structured progression through different phases. Phase I trials are the first step, primarily focused on determining whether a new medicine is safe and identifying the appropriate dose. These studies usually involve small numbers of participants. Phase II trials expand to more patients and begin examining whether the treatment actually helps reduce symptoms or alter the disease course. Phase III trials are large studies that compare the new treatment against standard treatments or placebo to definitively determine effectiveness.
Current research is exploring several promising directions. Some studies are investigating new ways to block interleukin-1, building on the success of anakinra and canakinumab. Other research examines medicines that target different inflammatory pathways, potentially offering options for patients who don't respond to IL-1 blocking drugs. Researchers are also studying combination approaches—using two or more medicines together that target different aspects of the inflammatory process.
One area of active investigation involves identifying biomarkers—measurable indicators in the blood or other body fluids—that can predict which patients will respond best to which treatments. Currently, doctors often must try different medicines sequentially to find what works for each individual patient. Biomarkers could potentially allow for more personalized treatment selection from the start. Studies have noted that extremely elevated levels of a protein called ferritin (often exceeding 1000 nanograms per milliliter) are characteristic of Still's disease, and researchers are exploring whether ferritin levels or other markers can guide treatment decisions.
Clinical trials for Still's disease take place in medical centers around the world, including locations in the United States, Europe, and other regions. Eligibility for these trials depends on factors such as the patient's age, disease duration, current treatments, and overall health. Some trials specifically seek patients who haven't responded well to standard therapies, while others may accept patients earlier in their disease course. Interested patients can discuss clinical trial options with their rheumatologist, who can help identify appropriate studies and explain what participation would involve.
Preliminary results from some clinical trials have shown encouraging signs. Studies of IL-1 blocking drugs in particular have demonstrated improvements in fever frequency, rash, joint pain, and blood test results indicating reduced inflammation. Some patients who had persistent disease despite other treatments achieved remission with these targeted therapies. Safety profiles have generally been acceptable, though as with all immunosuppressive treatments, increased infection risk is a concern that requires monitoring.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
